Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant

Launched by INSTITUTE OF LIVER AND BILIARY SCIENCES, INDIA · Dec 17, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how an antibiotic called rifaximin can help improve the function of a transplanted liver in adults who receive a liver from a living donor. After a liver transplant, some patients experience early graft dysfunction (EGD), which means the new liver doesn’t work as well as it should initially. This can lead to serious complications, including a higher risk of losing the new liver. Previous studies suggest that rifaximin can reduce the chances of EGD, but this trial aims to see if it is effective when given around the time of surgery for living donor liver transplants.

To participate in this study, you must be an adult who is scheduled to undergo a living donor liver transplant at the designated center. Unfortunately, those who cannot provide consent, have allergies to rifaximin, are receiving a second transplant, or are pediatric patients are not eligible. If you join the study, you will take rifaximin before and after your transplant, and researchers will monitor how well your new liver is functioning. This could be an important step in improving outcomes for liver transplant patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All recipients (adults) undergoing living donor liver transplant in ILBS.
• Exclusion Criteria:
• • Negative consent
• • Hypersensitivity to Rifaximin
• • Patients undergoing retransplant
• • ALF, ACLF
• • Pediatrics patients
• • Patients on rifaximin